Theranostics 2013; 3(10):787-801. doi:10.7150/thno.5629


Tumor Quantification in Clinical Positron Emission Tomography

Bing Bai1, James Bading2, Peter S Conti1 ✉

1. Department of Radiology, University of Southern California, Los Angeles, CA;
2. Department of Cancer Immunotherapy and Tumor Immunology, City of Hope, Duarte, CA.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See for full terms and conditions.
Bai B, Bading J, Conti PS. Tumor Quantification in Clinical Positron Emission Tomography. Theranostics 2013; 3(10):787-801. doi:10.7150/thno.5629. Available from

File import instruction


Positron emission tomography (PET) is used extensively in clinical oncology for tumor detection, staging and therapy response assessment. Quantitative measurements of tumor uptake, usually in the form of standardized uptake values (SUVs), have enhanced or replaced qualitative interpretation. In this paper we review the current status of tumor quantification methods and their applications to clinical oncology. Factors that impede quantitative assessment and limit its accuracy and reproducibility are summarized, with special emphasis on SUV analysis. We describe current efforts to improve the accuracy of tumor uptake measurements, characterize overall metabolic tumor burden and heterogeneity of tumor uptake, and account for the effects of image noise. We also summarize recent developments in PET instrumentation and image reconstruction and their impact on tumor quantification. Finally, we offer our assessment of the current development needs in PET tumor quantification, including practical techniques for fully quantitative, pharmacokinetic measurements.

Keywords: Positron emission tomography, tumor quantification